• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by NextCure Inc.

    4/1/24 6:34:24 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email
    SC 13G 1 nxtc13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)

    NextCure, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    65343E108

    (CUSIP Number)

    April 1, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 65343E108

     

     

    1.Names of Reporting Persons.

    Logos Global Management LP

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,000,460
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,000,460

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,000,460

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12.Type of Reporting Person (See Instructions) IA, PN

     2 
    CUSIP No. 65343E108

     

     

    1.Names of Reporting Persons.

    Logos Global Management GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,000,460
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,000,460

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,000,460

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12.Type of Reporting Person (See Instructions) HC, OO

     

     3 
    CUSIP No. 65343E108

     

     

    1.Names of Reporting Persons.

    Arsani William

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,000,460
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,000,460

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,000,460

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 65343E108

     

     

    1.Names of Reporting Persons.

    Logos Global Master Fund LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ___X__

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,000,460
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,000,460

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,000,460

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     5 
    CUSIP No. 65343E108

     

     

    1.Names of Reporting Persons.

    Logos GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 2,000,460
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 2,000,460

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,000,460

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12.Type of Reporting Person (See Instructions) OO

     

     6 
    CUSIP No. 65343E108

     

     

    Item1.
    (a)Name of Issuer

    NextCure, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    9000 Virginia Manor Road, Suite 200, Beltsville, MD 20705

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    Logos Global Master Fund LP (“Global Fund”), Logos Global Management LP (“Logos Global”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), and Arsani William (collectively, the “Filers”).

     

    Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos Global GP.

     

    The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 65343E108.
     7 
    CUSIP No. 65343E108

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Logos Global.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) as to Logos Global GP and Dr. William.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 27,903,027 shares of Common Stock outstanding as of March 18, 2024, as reported in the Form 10-K filed by the Issuer on March 21, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Global Fund holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of Logos Global, Logos Global GP and Dr. William:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Global Fund and Logos GP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 65343E108

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 1, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     9 
    CUSIP No. 65343E108

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: April 1, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

     

    Get the next $NXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

      Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported first quarter 2025 financial results. "With our LNCB74 antibody-drug conjugate ("ADC") program completing coho

      5/1/25 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

      BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative m

      4/4/25 7:00:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Provides Business Update and Reports Full Year 2024 Financial Results

      Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results. "In 2024 we reprioritized our resources to advance our antibody-drug conjugate ("ADC") program and recently completed cohor

      3/6/25 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NextCure Inc.

      SC 13G/A - NextCure, Inc. (0001661059) (Subject)

      11/14/24 6:59:21 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NextCure Inc.

      SC 13G/A - NextCure, Inc. (0001661059) (Subject)

      11/13/24 4:06:36 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by NextCure Inc.

      SC 13G - NextCure, Inc. (0001661059) (Subject)

      6/27/24 4:47:26 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Guha Udayan

      3 - NextCure, Inc. (0001661059) (Issuer)

      2/6/25 4:16:36 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.

      4 - NextCure, Inc. (0001661059) (Issuer)

      2/3/25 6:23:04 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Mayer Timothy

      4 - NextCure, Inc. (0001661059) (Issuer)

      2/3/25 6:22:50 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NextCure downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded NextCure from Buy to Neutral

      11/4/22 1:03:13 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on NextCure with a new price target

      Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

      3/1/22 7:18:07 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on NextCure with a new price target

      Needham reiterated coverage of NextCure with a rating of Buy and set a new price target of $14.00 from $30.00 previously

      11/5/21 8:42:25 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

      BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

      4/4/24 7:05:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

      BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

      10/27/22 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

      BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

      3/4/21 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by NextCure Inc.

      SCHEDULE 13G - NextCure, Inc. (0001661059) (Subject)

      5/12/25 12:54:33 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by NextCure Inc.

      10-Q - NextCure, Inc. (0001661059) (Filer)

      5/1/25 4:25:27 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NextCure, Inc. (0001661059) (Filer)

      5/1/25 4:15:24 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Financials

    Live finance-specific insights

    See more
    • NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

      BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

      11/1/21 8:00:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care